Document is current
Any future updates will be listed below
-
Authors
Cosmi, B.
Giannella, M.
Fornaro, G.
Cristini, F.
Patacca, A.
Castagna, A.
Mazzaferri, F.
Testa, S.
Pan, A.
Lupi, M.
Brambilla, P.
Montineri, A.
Frattima, S.
Bignami, E. G.
Salvetti, M.
De Stefano, G.
Grandone, E.
Di Perri, G.
Rozzini, R.
Stella, A.
Romagnoli, A.
Drago, F.
Viale, P.
- License Information
-
More Information
Article History
Received: 27 July 2022
Accepted: 30 April 2023
First Online: 24 October 2023
Declarations
:
: The study was approved by the Ethics Committee of the Lazzaro Spallanzani National Institute for Infectious Diseases of Rome which has been attributed the role of National Ethics Committee for assessing clinical trials on medicines for human use and medical devices for patients with COVID-19 and by the Italian Drug Agency (AIFA), EudraCT Number: 2020-001308-40. Informed consent was obtained from all enrolled patients.The study was performed in accordance with relevant guidelines/regulations.Informed consent was obtained from all participants and/or their legal guardians.
: Not applicable.
: B. Cosmi received speakers honoraria by Sanofi, Werfen IL, fees for advisory board from Viatris and Techdow Pharma Italy; E. Grandone received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Sanofi, ItalFarmaco, Rovi, Stago Werfen; A. Castagna received consulting fees, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events and participated to Data Safety Monitoring Board or Advisory Board from MSD, Gilead Sciences, Jannsen Cilag and Viiv Healthcare and Theratechnologies; A. Stella received consulting fees from Techdow Pharma Italy; A. Romagnoli is employed by Ricerche Nuove Pisa, Italy and received Contract from Techdow Italy Srl for the INHIXACOVID19 Study Management. Other authors declare no known competing financial interest or personal relationship that could have appeared influence the study.
